生物医学および医薬品の研究におけるヒトの代謝の個性
Karsten Suhre1,2,3, So-Youn Shin4, Ann-Kristin Petersen5
1Institute of Bioinformatics and Systems Biology, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany.
Nature
|September 3, 2011
まとめ
この研究は,遺伝的変異を代謝的特徴と関連付け,37の遺伝的位置を特定しました. 25の局所に対して高い効果の大きさは,複雑な疾患とパーソナライズされた医療に関する新しい洞察を提供します.
科学分野:
- 遺伝学 遺伝学とは
- メタボロミクスとは
- システム生物学 システム生物学
背景:
- ゲノム・ワイド・アソシエーション・スタディ (GWAS) は,疾患リスクの位置を特定しますが,しばしば生物学的洞察が欠け,効果のサイズが小さいことが示されています.
- 代謝的特徴は,遺伝的関連と疾患メカニズムを橋渡しする機能的中間体として機能し,個別化された治療法に潜在的に情報を与える可能性があります.
研究 の 目的:
- ゲノム・ワイド・アソシエーション・スタディ (GWAS) と非標的メタボロミクスを組み合わせて,ゲノム型に依存した代謝フェノタイプを包括的に分析する.
- 血液中の代謝産物濃度に関連した遺伝的位置を特定し,その効果の大きさと複雑な疾患に対する潜在的な機能的影響を調査する.
主な方法:
- 全ゲノム関連研究 (GWAS) のアプローチを使用しました.
- メタボリックフェノタイプを分析するために統合された非ターゲティングのメタボロミクス.
- 遺伝子型に依存する代謝データの包括的な分析を行いました.
主要な成果:
- 血液中の代謝産物濃度に関連した37の遺伝的位置を特定しました.
- これらのロシの25個がGWASに対して異常に高い効果サイズを示し,アレルコピーあたり10~60%の代謝物レベルの変動を説明することを発見した.
- 以前に報告された疾患に関連する遺伝的関連に関する新しい機能的洞察を提供した.
結論:
- この発見は,ヒトの代謝的個性の遺伝的基礎の理解を前進させる.
- 特定された関連は,生物医学および医薬品の研究のための新しい仮説を提供し,特に心血管および腎臓疾患,2型糖尿病,癌,痛風,静脈血栓栓塞栓症,クローン病などの分野において,特に重要です.
関連する概念動画
01:24Dosage Regimen: Individualization
398
Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
398
01:27Principles of Pharmacogenetics: Types of Genetic Variants
138
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
138
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
159
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
159
01:27Pharmacogenetics of Drug Metabolism: Overview
194
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
194
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
338
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
338
01:16Drug toxicity: Idiosyncratic Reactions
220
Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
220